Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation

25 Feb 2022

Abstract excerpt

Large-scale molecular profiling and genotyping provide a unique opportunity to systematically compare the genetically predicted effects of therapeutic targets on the human metabolome. We firstly constructed genetic risk scores for 8 drug targets on the basis that they primarily modify low-density lipoprotein (LDL) cholesterol (HMGCR, PCKS9, and NPC1L1), high-density lipoprotein (HDL) cholesterol (CETP), or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Associations and Epidemiology
Share to Lipid metabolism and disorders
Share to Metabolomics and Mass Spectrometry Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35213538
DOI: 10.1371/journal.pbio.3001547

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisationPMID 35213538Read ↗

Metabolomic signatures of lipid-modifying therapies using drug target Mendelian randomizationSemantic proximity Read ↗

Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study.Semantic proximity Read ↗

Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease riskSemantic proximity Read ↗

Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease riskSemantic proximity Read ↗

A factorial Mendelian randomization study to systematically prioritize genetic targets for the treatment of cardiovascular diseaseSemantic proximity Read ↗

Validation of lipid-related therapeutic targets for coronary heart disease prevention using human geneticsSemantic proximity Read ↗

Validation of lipid-related therapeutic targets for coronary heart disease prevention using human geneticsSemantic proximity Read ↗

Validation of lipid-related therapeutic targets for coronary heart disease prevention using human geneticsSemantic proximity Read ↗

Effects of genetically proxied lipid-lowering drugs on acute myocardial infarction: a drug-target mendelian randomization study.Semantic proximity Read ↗

Causal effects of lipid-lowering therapies on aging-related outcomes and risk of cancers: a drug-target Mendelian randomization study.Semantic proximity Read ↗

Genetically instrumented LDL-cholesterol lowering and multiple disease outcomes: A Mendelian randomization phenome-wide association study in the UK Biobank.Semantic proximity Read ↗

Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.